Pretzel Therapeutics Snares $72.5M Series A

Funding Rounds

▤ Summary

Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched with a $72.5 million Series A financing to pioneer novel therapies to modulate mitochondrial function. The financing was led by ARCH Venture Partners and Mubadala Capital with participating investors HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, GV, Invus, Eir Ventures, GU Ventures, and Karolinska Institutet Holding. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

$ Funding

$
Amount - Total raised
□
Date - Announcement date
◎
Investors Video Island Lead investors
▥
Company - Funded company

▥ Classifications

industries
Fintech & Banking
applications
Accounting and Taxes

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies